- $1.63bn
- $3.68bn
- $1.76bn
- 37
- 96
- 40
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.3 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.92 | ||
| EV to EBITDA | 0.63 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 140.5% | ||
| Return on Equity | n/a | ||
| Operating Margin | 306.35% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 2,993.21 | 2,318.88 | 2,011.52 | 1,760.14 | n/a | n/a | -16.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Endo, Inc. is a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The Branded Pharmaceuticals segment includes a variety of branded products in the therapeutic areas of urology, orthopedics, endocrinology and bariatrics, among others. Its products include XIAFLEX, SUPPRELIN LA, AVEED, PERCOCET, TESTOPEL, and EDEX. The Sterile Injectables segment consists primarily of branded sterile injectable products, such as ADRENALIN, VASOSTRICT, APLISOL and certain generic sterile injectable products. The Generic Pharmaceuticals segment consists of solid oral extended-release products and solid oral immediate-release products. The International Pharmaceuticals segment includes a variety of specialty pharmaceutical products, including over-the-counter (OTC) products, sold outside the United States.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 5th, 2023
- Public Since
- June 27th, 2024
- No. of Shareholders
- 41
- No. of Employees
- 3,116
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 76,211,329
- Address
- 1400 Atwater Drive, MALVERN, 19355
- Web
- https://www.endo.com/
- Phone
- +1 4842160000
- Auditors
- PricewaterhouseCoopers LLP (USA)
Upcoming Events for NDOI
Q1 2025 Endo Inc Earnings Release
Q2 2025 Endo Inc Earnings Release
Similar to NDOI
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the Endo share price?
As of Today at 20:26 UTC, shares in Endo are trading at $21.35. This share price information is delayed by 15 minutes.
How has the Endo share price performed this year?
Shares in Endo last closed at $21.35 and the price had moved by over the past 365 days. In terms of relative price strength the Endo share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Endo?
There is no consensus recommendation for this security.
Find out moreWhat is the Endo dividend yield?
Endo does not currently pay a dividend.
Does Endo pay a dividend?
Endo does not currently pay a dividend.
When does Endo next pay dividends?
Endo does not currently pay a dividend.
How do I buy Endo shares?
To buy shares in Endo you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Endo?
As of the previous close price of $21.35, shares in Endo had a market capitalisation of $1.63bn.
Where are Endo shares listed?
Here are the trading details for Endo:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NDOI
What kind of share is Endo?
Based on an overall assessment of its quality, value and momentum Endo is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Endo share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Endo share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Endo. Over the past six months, its share price has underperformed the S&P500 Index by -15%.
As of the last closing price of $21.35, shares in Endo were trading -16.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Endo PE Ratio?
The Endo PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $21.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Endo?
We do not have data on Endo's directors